Halozyme Therapeutics Sinks on Business Update
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 230
Celgene Disappoints Investors by Meeting Estimates
Celgene Corp. (NASDAQ: CELG) sank in Monday's session after providing a business update that was largely in line with analyst expectations.
Anavex Soars on Positive Alzheimer’s Results
Anavex Life Sciences was one of the stocks helping to prop up the market in Monday’s session.
Clearside Files for IPO
Clearside Biomedical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
3 Biotech Stocks With 2016 Phase 3 Data That Could Have Huge Upside Potential
A new RBC report focuses on top biotech stocks with key data readouts coming in 2016. These three seem to be the farthest along and offer the best chance for approval.
Is Thermo Fisher Overpaying for Affymetrix?
Affymetrix was absolutely soaring early on Monday on word that it will be acquired. Thermo Fisher Scientific is the buyer.
Athersys Soars on Japanese License Deal
Athersys has announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments.
Ardelyx Gears Up for Secondary Offering
Ardelyx recently filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
Merrill Lynch Has 4 Safe Dividend-Paying Mega-Cap Pharmaceutical Stocks to Buy
One good plan for stockholders who are seeing gains evaporate is to rotate to a more defensive sector. Large cap pharmaceutical stocks totally fit the bill.
Collegium Pharmaceutical Prices Secondary Offering
Collegium Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.
Jaguar Animal Health Gears Up for Secondary Offering
Jaguar Animal Health has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
4 Pharmaceutical Stocks With Big Catalysts Pending in 2016
This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny. These four companies with promising candidates all have dates with the agency this year.
Dynavax Soars on Positive Late Stage Results
Dynavax Technologies led the bulls on Thursday with positive results from a late stage clinical trial, on another consecutive down day for the broad markets.
Visterra Readies for IPO
Visterra has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson
24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case for each in 2016.